<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965949</url>
  </required_header>
  <id_info>
    <org_study_id>HRT001</org_study_id>
    <nct_id>NCT03965949</nct_id>
  </id_info>
  <brief_title>Different Strategies in Frozen IVF/ICSI Cycles</brief_title>
  <official_title>Impact of Different Strategies in Frozen Cycles Using HRT in Normo Responding Patients Undergoing IVF/ICSI Cycles: a Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the absence of robust contemporary data, we decided to perform a multicenter cohort study
      of various IVF centers, to compare the different modalities used for pregnancy rates
      following frozen-thawed embryo transfer (FET) treatment cycles in normoovulatory patients
      undergoing IVF/ICSI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In general, the type of FET protocol for each patient is selected by the attending physicians
      at their own discretion. In all centers, patients with ovulatory cycles are typically
      prescribed an NC-FET or mNC-FET, whereas patients with oligomenorrhoea or amenorrhoea are
      prescribed an artificial cycle to prepare the endometrium for FET.

      Ovarian stimulation protocol

        1. The antagonist protocol

        2. The long 21 /2 agonist protocol Laboratory technique

      a. IVF or b. ICSI Embryo freezing using only vitrification will be performed in days 3 or
      5/6. Embryo transfer will be conducted at days 3 or 5/6. The maximum number of embryos
      transferred will be two, as in accordance to the Hellenic legislation.

      The following modalities will be analyzed, patients with:

        1. Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without
           luteal support (Group 1)

        2. Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with
           luteal support (progesterone) (Group 2)

        3. Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support
           (progesterone) (Group 3)

        4. Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support
           (progesterone) (Group 4)

      Of note, the conversion between different supplementation methods may be testimated as
      follows: 0.75 mg of micronised estradiol (oral administration) = 1.25 g of estradiol gel
      (transdermal administration) = 1 mg of estradiol valerate (oral or vaginal adminstration).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>live birth</measure>
    <time_frame>1 year</time_frame>
    <description>birth after 20 weeks of gestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ongoing pregnancy</measure>
    <time_frame>3 months</time_frame>
    <description>positive heart rate after 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miscarriage</measure>
    <time_frame>6 months</time_frame>
    <description>pregnancy loss up to 20 weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical pregnancy (positive β-hCG), multiple, ectopic and clinical pregnancy rates</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>the Different Modalities Used for Pregnancy Rates Following Frozen-thawed Embryo Transfer (FET) Treatment Cycles</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement cycle 1</intervention_name>
    <description>Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement cycle 2</intervention_name>
    <description>Hormone Replacement cycle with GnRHa suppression</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Following clinical evaluation along with previous medical and reproductive history,
        participants will be categorized according to the subfertility factor and further
        demographic parameters (age, Body Mass Index (BMI), smoking status, basal FSH levels,
        parity, antral follicle count (AFC) in the fresh cycle, type (primary/secondary) and
        duration of subfertility and number of unsuccessful IVF/ICSI attempts (fresh and/or frozen)
        will be recorded along with the respective hormonal profiles.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        age 25-39 years, BMI ≤ 35 and ≥ 19, normo-ovulatory patients and basal FSH ≤11 mIU/mL.
        Definition of expected normal ovarian response will be based primarily on antral follicle
        count (AFC) between 6-14.

        Exclusion Criteria:

        history of more than three previous unsuccessful IVF/ICSI cycles, FSH &gt; 12 mIU/mL, BMI &gt;35
        or &lt;19, poor ovarian response according to the 2011 Bologna criteria, PCOS patients
        according to the Rotterdam criteria, history of untreated autoimmune, endocrine or
        metabolic disorders, history of pathology affecting the endometrial cavity and/or
        receptivity and clinical and/or laboratory markers of hereditary or acquired thrombophilia
        that complied to the standard protocols of each Unit and patients without embryo after
        thawing.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Charalampos Siristatidis, Professor</last_name>
      <phone>6932294994</phone>
      <email>harrysiri@yahoo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Professor in Obstetrics Gynaecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will discuss it with other authors</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

